In order to deepen the construction and development of the "Quality Year" and further enhance the quality awareness and level of all employees, Leecan organized an annual quality training in November 2024. All GMP system employees, including production system and quality system, participated in the training. The research institute also attended some training courses

This annual centralized training is divided into 8 sessions, mainly focusing on the detailed interpretation of the 2023 version of GMP guidelines, EU GMP Appendix 1, data integrity, and the company's quality management standards. The quality manager and authorized person of Leecan Pharmaceutical took the lead in sharing the "Interpretation of Appendix 1 of EU GMP: Pollution Control Strategies" with the trainees. Seven other outstanding lecturers also gave lectures one after another, presenting a "nutritious" training feast for the employees with practical experience, detailed lectures on typical cases, and practical video explanations! Accumulated participation of 479 people, and organized a closed book exam on the training content one week after the end of the training. The pass rate of the first exam was 89%, and the pass rate of the re exam was 100%, successfully achieving the training objectives and achieving good training results.

Leecan always adheres to the development concept of "quality as the foundation", attaches great importance to the construction of quality system and the improvement of quality level, and continues to empower the company's quality management through various forms such as external training, internal training, skill competitions, and knowledge competitions, effectively consolidating the management foundation and building a solid quality defense line. Leecan Pharmaceutical adheres to strict compliance with domestic and international GMP and company quality management requirements, implementing the strictest control over every step of production and inspection process, and developing and producing high-quality drugs that "reassure patients, regulators, society and us", benefiting the vast number of patients with domestically produced good drugs of national independent brands